

CIMBA Polygenic Risk Score Variables (using OncoArray and iCOGS data)		
Name	Description	CIMBA publication
bc_313_raw_prs	Raw (unstandardised) overall breast cancer 313 SNP PRS (based on Mavaddat et al, Am J Hum Genet, 2019)	Barnes et al, Genet in Med 2020
bc_313_norm_prs	Standardised breast cancer 313 SNP PRS, centred around 0 and scaled by the observed standard deviation from the BCAC controls, SD=0.6093 (based on Mavaddat et al, Am J Hum Genet, 2019)	Barnes et al, Genet in Med 2020
en_313_raw_prs	Raw (unstandardised) overall ER-negative breast cancer 313 SNP PRS (based on Mavaddat et al, Am J Hum Genet, 2019)	Barnes et al, Genet in Med 2020
en_313_norm_prs	Standardised ER-negative breast cancer 313 SNP PRS, centred around 0 and scaled by the observed standard deviation from the BCAC controls, SD=0.592 (based on Mavaddat et al, Am J Hum Genet, 2019)	Barnes et al, Genet in Med 2020
ep_313_raw_prs	Raw (unstandardised) overall ER-positive breast cancer 313 SNP PRS (based on Mavaddat et al, Am J Hum Genet, 2019)	Barnes et al, Genet in Med 2020
ep_313_norm_prs	Standardised ER-positive breast cancer 313 SNP PRS, centred around 0 and scaled by the observed standard deviation from the BCAC controls, SD=0.652 (based on Mavaddat et al, Am J Hum Genet, 2019)	Barnes et al, Genet in Med 2020
oc_30_raw_prs	Raw (unstandardised) ovarian cancer PRS (not published) based on 30 SNPs reported in Phelan et al, Nat Genet, 2017. These SNPs were found to be associated with ovarian cancer (any histotype) by OCAC or OCAC+CIMBA meta-analysis, or were pleiotropic associations for br ca/ov ca/prostate ca (Kar et al, Cancer Discov, 2016)	Barnes et al, Genet in Med 2020
oc_30_norm_prs	Standardised ovarian cancer PRS (not published) based on 30 SNPs reported in Phelan et al, 2017, Nat Genet. These SNPs were found to be associated with ovarian cancer (any histotype) by OCAC or OCAC+CIMBA meta-analysis, or were pleiotropic associations for br ca/ov ca/prostate ca (Kar et al, Cancer Discov, 2016). Centred around 0 and scaled by the observed SD in carriers without ovarian cancer (SDs calculated separately in BRCA1 and in BRCA2 carriers)	Barnes et al, Genet in Med 2020
hgs_22_raw_prs	Raw (unstandardised) high-grade serous ovarian cancer PRS (not published) based on a 22 SNP subset from the 30 SNPs mentioned above that were genome-wide significant ($P < 5 \times 10^{-8}$) with any ov ca histotype, were nominally associated with HGS ov ca ($P < 0.05$), and had the same direction of effect between overall ov ca and HGS ov ca.	Barnes et al, Genet in Med 2020
hgs_22_norm_prs	Standardised high-grade serous ovarian cancer PRS (not published) based on a 22 SNP subset from the 30 SNPs mentioned above that were genome-wide significant ($P < 5 \times 10^{-8}$) with any ov ca histotype, were nominally associated with HGS ov ca ($P < 0.05$), and had the same direction of effect between overall ov ca and HGS ov ca. Centred around 0 and scaled by the observed SD in carriers without ovarian cancer (SDs calculated separately in BRCA1 and in BRCA2 carriers)	Barnes et al, Genet in Med 2020
bc_313_raw_prs_males	Raw (unstandardised) overall breast cancer 313 SNP PRS (based on Mavaddat et al, Am J Hum Genet, 2019) for male carriers	Barnes et al, JNCI, 2021
bc_313_norm_prs_males	Standardised breast cancer 313 SNP PRS, centred around 0 (in the combined set of BRCA1/2 samples) and scaled by the observed standard deviation from the BCAC controls, SD=0.6093 (based on Mavaddat et al, Am J Hum Genet, 2019) for male carriers	Barnes et al, JNCI, 2021
ep_313_raw_prs_males	Raw (unstandardised) overall ER-positive breast cancer 313 SNP PRS (based on Mavaddat et al, Am J Hum Genet, 2019) for male carriers	Barnes et al, JNCI, 2021
ep_313_norm_prs_males	Standardised ER-positive breast cancer 313 SNP PRS, centred around 0 (in the combined set of BRCA1/2 samples) and scaled by the observed standard deviation from the BCAC controls, SD=0.652 (based on Mavaddat et al, Am J Hum Genet, 2019) for male carriers	Barnes et al, JNCI, 2021
en_313_raw_prs_males	Raw (unstandardised) overall ER-negative breast cancer 313 SNP PRS (based on Mavaddat et al, Am J Hum Genet, 2019) for male carriers	Barnes et al, JNCI, 2021
en_313_norm_prs_males	Standardised ER-negative breast cancer 313 SNP PRS, centred around 0 (in the combined set of BRCA1/2 samples) and scaled by the observed standard deviation from the BCAC controls, SD=0.592 (based on Mavaddat et al, Am J Hum Genet, 2019) for male carriers	Barnes et al, JNCI, 2021
pc_147_raw_prs_males	Raw (unstandardised) prostate cancer 147 SNP PRS (based on Schumacher et al, Nat Genet, 2018)	Barnes et al, JNCI, 2021
pc_147_norm_prs_males	Standardised prostate cancer 147 SNP PRS, centred around 0 (in the combined set of BRCA1/2 samples) and scaled by the observed standard deviation from the PRACTICAL controls, SD=0.6890579 (based on Schumacher et al, Nat Genet, 2018)	Barnes et al, JNCI, 2021
oc_22_stepwise_raw_prs	Raw (unstandardised) ovarian cancer 22 SNP stepwise PRS (based on Dareng et al, EJHG, 2021)	Dareng et al, EJHG, 2021
oc_22_stepwise_norm_prs	Standardised ovarian cancer 22 SNP stepwise PRS, centred around 0 and scaled by the observed standard deviation from the OCAC controls, SD=0.297 (based on Dareng et al, EJHG, 2021)	Dareng et al, EJHG, 2021
oc_10797_enet_raw_prs	Raw (unstandardised) ovarian cancer 10,797 SNP elastic net PRS (based on Dareng et al, EJHG, 2021)	Dareng et al, EJHG, 2021
oc_10797_enet_norm_prs	Standardised ovarian cancer 10,797 SNP elastic net PRS, centred around 0 and scaled by the observed standard deviation from the OCAC controls, SD=0.222 (based on Dareng et al, EJHG, 2021)	Dareng et al, EJHG, 2021
oc_1403_lasso_raw_prs	Raw (unstandardised) ovarian cancer 1,403 SNP lasso PRS (based on Dareng et al, EJHG, 2021)	Dareng et al, EJHG, 2021
oc_1403_lasso_norm_prs	Standardised ovarian cancer 1,403 SNP lasso PRS, centred around 0 and scaled by the observed standard deviation from the OCAC controls, SD=0.235 (based on Dareng et al, EJHG, 2021)	Dareng et al, EJHG, 2021
oc_27240_ocacs4_raw_prs	Raw (unstandardised) ovarian cancer 27,240 SNP OCAC select and shrink PRS (based on Dareng et al, EJHG, 2021)	Dareng et al, EJHG, 2021
oc_27240_ocacs4_norm_prs	Standardised ovarian cancer 27,240 SNP OCAC select and shrink PRS, centred around 0 and scaled by the observed standard deviation from the OCAC controls, SD=0.348 (based on Dareng et al, EJHG, 2021)	Dareng et al, EJHG, 2021
oc_27240_ocacs4_norm_prs	The 36 SNP OCAC-CIMBA stepwise PRS and the 18,007 SNP OCAC-CIMBA select and shrink PRS are deliberately omitted. These PRS overfit to CIMBA data as CIMBA carrier data was used in the derivation of these PRS.	Dareng et al, EJHG, 2021